Emerging Tau-Targeting Antibody for Alzheimer’s Disease Gets FDA Fast Track Designation

Preliminary research findings have shown that the investigational anti-microtubule binding region (MTBR) tau antibody etalanetug may help reduce a biomarker for brain tau pathophysiology and tau signals on positron emission tomography (PET).

Read the full article on diagnosticimaging.com